Publications by authors named "Lee Albacker"

Claim this Profile
S
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Badeel Kh Q Zaghla, Zuhal Safyürek, Daniela Gröger, Shima Mecklenbräuker, Nina-Sophie Lingstädt, Lee A Albacker

J Immunother Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.
Karim Fizazi, Johann S de Bono, A Douglas Laird, Philippe Barthélémy, Rémy Delva, Lee A Albacker

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity.
Julius Honecker, Dirk Paffenholz, Julian Jungmann, Thomas Wieland, Angela A Kou, Lee A Albacker

J Mol Diagn· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
April A Apfelbaum, Eric Morin, Dominik Sturm, Georges Ayoub, Jeromy DiGiacomo, Lee A Albacker

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy.
Derek W Brown, Daokun Sun, Alexander D Fine, Shai He, Michael McDevitt, Lee A Albacker

J Liq Biopsy· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical validation (accuracy, reproducibility, limit of detection) and gene expression analysis of FoundationOneRNA assay for fusion detection in 189 clinical tumor specimens.
Daokun Sun, Richard S P Huang, Michelle Green, Chenming Cui, Saumya D Sisoudiya, Lee A Albacker

PLoS One· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Specificity Detection of UV Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors Using FoundationOne Liquid CDx.
Douglas A Mata, Angela A Kou, Andreas M Heilmann, Julius Honecker, Benjamin R Kroger, Lee A Albacker

J Mol Diagn· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
April A Apfelbaum, Eric Morin, Dominik Sturm, Georges Ayoub, Jeromy DiGiacomo, Lee A Albacker

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Lee Albacker

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Zachary Risch, Benjamin H Kaffenberger, Catherine G Chung, Eric Samorodnitsky, Emily L Hoskins, Lee A Albacker

Haematologica· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Lee Albacker

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Lee A Albacker

Breast Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab.
Douglas I Lin, Julia C F Quintanilha, Natalie Danziger, Lixin Lang, Diane Levitan, Lee A Albacker

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors.
James F Haberberger, Worthy Pegram, Nicholas Britt, Kelsie Schiavone, Eric Severson, Lee A Albacker

Oncologist· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
Jie He, Natallia Kalinava, Parul Doshi, Dean C Pavlick, Lee A Albacker

J Immunother Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Lee A Albacker

NPJ Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content.
Radwa Sharaf, Dexter X Jin, John Grady, Christine Napier, Ericka Ebot, Lee A Albacker

NPJ Genom Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting EGFR mutational status from pathology images using a real-world dataset.
James J Pao, Mikayla Biggs, Daniel Duncan, Douglas I Lin, Richard Davis, Lee A Albacker

Sci Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.
Niamh Coleman, Kathrina L Marcelo, Julia F Hopkins, Nusrat Israr Khan, Robyn Du, Lee A Albacker

JCO Precis Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.
Emily L Hoskins, Eric Samorodnitsky, Michele R Wing, Julie W Reeser, Julia F Hopkins, Lee A Albacker

JCO Precis Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Karthikeyan Murugesan, Dexter X Jin, Leah A Comment, David Fabrizio, Priti S Hegde, Lee A Albacker

Oncologist· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors.
Radwa Sharaf, Garrett M Frampton, Lee A Albacker

PLoS One· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J Wu, Deepti Banka, Lee A Albacker

Mol Cancer Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.
Ericka M Ebot, Daniel L Duncan, Khaled Tolba, David Fabrizio, Garrett M Frampton, Lee A Albacker

NPJ Precis Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations.
Simon Papillon-Cavanagh, Julia F Hopkins, Shakti H Ramkissoon, Lee A Albacker, Alice M Walsh

Commun Med (Lond)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis